Posts

Posted on

Auvik’s Network Management Software Shows 173 Percent Return on Investment over Three Years According to New Total Economic Impact Study by Independent Research Firm

New study shows how Auvik improved network visibility and automated capabilities, saving millions of dollars

WATERLOO, ON, May 04, 2021 (GLOBE NEWSWIRE) — Auvik, an award-winning provider of cloud-based network management software, today released a commissioned study conducted by Forrester Consulting that quantifies the total economic impact and benefits of Auvik’s solution. In the study, Forrester found that enterprises implementing Auvik obtained a return on investment (ROI) of 173% over three years. 

Auvik is cloud-based network management software that can provide actionable intelligence on a network in under 30 minutes in a simple, intuitive interface, designed to scale with a business. Through a single dashboard, it offers automated network discovery, inventory, and documentation; simplified network performance monitoring and troubleshooting; and automated configuration backup and recovery—Auvik converts dozens of time-consuming tasks into simple, automated steps. With support for over 15,000+ devices from over 700 vendors, Auvik is the present and future of network monitoring and management, accelerating an IT team’s efficiency and capacity while protecting the business from network risk. 

“As we continue to shift to a remote-first world, the importance of networks and the critical function they play in our daily lives is increasingly evident,” said Marc Morin, CEO of Auvik Networks. “We believe this Forrester study affirms how Auvik improves IT team efficiency with a consolidated automated system, offering great network performance visibility, significant efficiencies in issue detection and resolution, and deep network traffic insights.” 

Forrester interviewed Auvik customers to understand the benefits, costs, and risks associated with using the Auvik system. The firm then aggregated the results into a single composite organization to form a model for prospective customers to evaluate the potential quantifiable impact of deploying Auvik in their organization. 

The study’s results revealed significant cost savings and business benefits for IT organizations that have implemented Auvik. Over three years, Forrester’s analysis revealed an enterprise would realize significant cost savings, including: 

  • The ability to quickly remedy issues, automate configuration backups, and improve access to network documentation allows for over $1M in network monitoring time savings and reduces the network monitoring time by two hours per network per month.
  • Combining a mix of disparate network management tools into one system avoids $600K in legacy license costs.
  • Access to automated, real-time information in one central platform eliminates clunky, on-premise and manual tasks by network specialists, allowing network managers to redeploy staff to higher-level tasks and gain $567K in improved efficiencies.

According to an Auvik customer interviewed for the study, a chief technology officer at an IT services management company, “Auvik has a great ability to map the networks and automatically back up the configurations. It helps us tremendously from a troubleshooting standpoint by pinpointing where to look first.” 

Another interviewed customer, a director of managed services at an MSP, highlighted the efficiencies gained in task execution, “Auvik allows my first- and second- level technicians to troubleshoot issues rather than having to immediately escalate them to my level-three or level-four guys.”

To download The Total Economic Impact of Auvik’s Network Management Solution, visit auvik.com/total-economic-impact.

About Auvik Networks

Auvik’s cloud-based network management software keeps IT networks around the world running optimally. By automating and simplifying network management, Auvik helps rocket an IT team’s efficiency and capacity, while protecting the business from network risk. Auvik is one of the fastest growing North American technology companies, and is winner of the Deloitte Technology Fast 50, Deloitte Fast 500, and recognized as the #1 ranked Canadian company in the FT Americas’ Fastest Growing Companies 2020. Visit www.auvik.com or follow @AuvikNetworks on Twitter. Auvik is a registered trademark of Auvik Networks Inc.



Ved Khan
Auvik Networks Inc.
(519) 804-4700 x437
[email protected]

Posted on

Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021

Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021

CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 13, 2021, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 13, 2021, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2021 financial and operating results and to provide a business update.

Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through May 21, 2021, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 4996965.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

([email protected])

(442) 287-8963

Solebury Trout IR

Gitanjali Jain Ogawa

([email protected])

(646) 378-2949

Russo Partners – Media Relations

Nic Johnson or David Schull

[email protected]

[email protected]

(212) 845-4242

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Infectious Diseases Biotechnology Health Oncology

MEDIA:

Logo
Logo
Posted on

Seaport Global Strengthens Emerging Markets Efforts

Seaport Global Strengthens Emerging Markets Efforts

David Barbrack Joins as Managing Director

NEW YORK–(BUSINESS WIRE)–
David Barbrack has joined Seaport Global Securities LLC (“Seaport Global”) as Managing Director, Emerging Markets. This strategic hire of a thirty year industry veteran is indicative of Seaport Global’s commitment to development of the Emerging Markets business. David joins an experienced trading team at Seaport Global. His presence will enhance the firm’s existing capabilities and allow for increased product offerings across Latin American hard and local currency bond markets.

David joins Seaport Global most recently from Credit Suisse where, as a Director on the Emerging Markets desk, he led the market making effort for Latin American sovereign, quasi-sovereign and corporate hard currency bonds. Prior to Credit Suisse, as a Director at Deutsche Bank, David was a senior Latin American hard currency flow trader, with a broad mandate that encompassed various IG, HY & Distressed sovereign and quasi-sovereign credits. David’s substantial career includes positions at WestLB, Santander Securities, LTCB Latin America and MG-First Boston.

Michael Meyer, Head of Global Sales and Trading at Seaport Global, said, “David Barbrack is a strong addition to our Emerging Markets desk. We are confident his knowledge of the markets will prove an asset to our clients.”

Michael Meagher, CEO of Seaport Global, said, “David Barbrack exemplifies the sophistication and seniority of our salesforce. We look forward to continuing to strengthen our Emerging Markets team with hires of this caliber.”

About Seaport Global

Seaport Global Securities LLC is a full-service investment bank that offers capital markets, financial advisory, sales, trading and research services. Headquartered in New York with offices across the US and in Europe, The firm’s forward-thinking practitioners, backed by extensive knowledge, strong relationships and decades of experience, focus on meeting clients’ goals in all business and economic cycles. Visit www.seaportglobal.com.

Lisa Weiss

Managing Director, Human Resources

Seaport Global Holdings LLC

(212) 601-9071

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

InvestorBrandNetwork Announces The Dealmaker Show Interview with PlantX Life Inc. CEO Julia Frank

LOS ANGELES, May 04, 2021 (GLOBE NEWSWIRE) — via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Julia Frank, CEO of PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), the company behind the one-stop shop for everything plant-based, recently appeared on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff.

To hear the full podcast, visit The Dealmaker Show.

During the interview, Klaff inquired about the early days of PlantX, Frank’s background as an executive with some of the world’s largest automotive corporations, and how the plant-based movement is continuing to gain steam for individuals from a wide variety of backgrounds.

“I used to live in Miami and the Bahamas. That’s actually where I met the founder [of PlantX], Sean Dollinger. Sean is super experienced; he’s built multiple e-commerce platforms and companies. He’s been in the e-commerce space for over 20 years,” Frank explained. “He told me about his vision to found a company that provides a one-stop shop for everything plant-based. … When I met Sean … I was actually working for BMW for five years … but I always preferred to ride a bike. … I’m not really passionate about cars and the automotive industry. … I was already thinking that it was time to leave and do something else, and when Sean told me about his idea for PlantX, it really sounded like a company I would be passionate about.”

“When you are living a 100% plant-based lifestyle, of course there are companies out there that offer plant-based products. But let’s say you’re looking for a plant-based meat product or plant-based cosmetics or even plant-based pet foods, you would have to check on multiple different websites. There was not a one-stop shop like Amazon for plant-based products where you can basically find any plant-based product available on the market,” Frank added. “Sean founded the company in 2019 … and our website went live at the end of March 2020, which was basically the first month of lockdown from the pandemic. … We set up an e-commerce business that delivers plant-based products to your doorstep in the times of a lockdown. … It was unplanned right timing.”

“I invite everyone to try out a plant-based lifestyle and give it a shot. Maybe it works. Even if you decide to eat your steak three or four times per week and decide to be plant-based or vegetarian the other days, it’s totally fine,” Frank continued. “I just think, in general, we have to be more cautious about what we put into our bodies and also how we handle the whole meat industry. … I’m convinced that the plant-based market is not just a temporary trend. … It’s important to do in life what you’re really passionate about and what you love, and I’m really happy that I can do what I love and also help other people.”

Throughout the interview, Frank discussed the growth of the plant-based movement and how PlantX is working to support the industry by creating a resource for this community of like-minded individuals to celebrate and promote health and well-being.

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand – but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

For more information, visit the company’s website at www.PlantX.com and the PlantX investor website at https://investor.PlantX.com.

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]



Posted on

Duluth Holdings Inc. to Report First Quarter 2021 Financial Results on June 3

MOUNT HOREB, Wis., May 04, 2021 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s casual wear, workwear and accessories, today announced that it will report first quarter 2021 financial results before market on Thursday, June 3, 2021.

A conference call and audio webcast with analysts and investors will be held on Thursday, June 3, 2021 at 9:30 am Eastern Time, to discuss the results and answer questions.

  • Live conference call: 844-875-6915 (domestic) or 412-317-6711 (international)
  • Conference call replay available through June 17, 2021: 877-344-7529 (domestic) or 412-317-0088 (international)
  • Replay access code: 10156187
  • Live and archived webcast: ir.duluthtrading.com        

To expedite entry into the call and avoid waiting for a live operator, investors may pre-register at http://dpregister.com/10156187 and enter their contact information. Investors will then be issued a personalized phone number and pin to dial into the live conference call. The first quarter 2021 earnings release can be accessed at ir.duluthtrading.com before market on Thursday, June 3, 2021.

About Duluth Trading

Duluth Trading is a growing lifestyle brand for the Modern, Self-Reliant American. Based in Mount Horeb, Wisconsin, we offer high quality, solution-based casual wear, workwear and accessories for men and women who lead a hands-on lifestyle and who value a job well-done. We provide our customers an engaging and entertaining experience. Our marketing incorporates humor and storytelling that conveys the uniqueness of our products in a distinctive, fun way, and our products are sold exclusively through our content-rich website, catalogs, and “store like no other” retail locations. We are committed to outstanding customer service backed by our “No Bull Guarantee” – if it’s not right, we’ll fix it. Visit our website at www. duluthtrading.com.

Investor and Media Contacts:

Donni Case (310) 622-8224
Margaret Boyce (310) 622-8247
Financial Profiles, Inc.
[email protected]



Posted on

Splunk to Announce Fiscal 2022 First Quarter Results on June 2, 2021

Splunk to Announce Fiscal 2022 First Quarter Results on June 2, 2021

SAN FRANCISCO–(BUSINESS WIRE)–Splunk Inc. (NASDAQ: SPLK), provider of the Data-To-Everything Platform, will report results for its first quarter ended April 30, 2021 on Wednesday, June 2, 2021. Results will be included in a press release with accompanying financial information that will be released after market close and posted on the Splunk Investor Relations website.

Splunk’s executive management team will host a conference call beginning at 1:30 p.m. PT (4:30 p.m. ET) to discuss financial results and business highlights. Interested parties may access the call by dialing (866) 501-1535 in the U.S. or (216) 672-5582 from international locations. In addition, a live audio webcast of the conference call will be available on the Splunk Investor Relations website at http://investors.splunk.com.

Shortly after the conclusion of the conference call, a replay of the audio webcast will be available on the Splunk Investor Relations website for approximately seven days.

About Splunk Inc.

Splunk Inc. (NASDAQ: SPLK) turns data into doing with the Data-to-Everything Platform. Splunk technology is designed to investigate, monitor, and analyze and act on data at any scale.

Splunk, Splunk>, Data-to-Everything, D2E and Turn Data Into Doing are trademarks and registered trademarks of Splunk Inc. in the United States and other countries. All other brand names, product names, or trademarks belong to their respective owners. © 2021 Splunk Inc. All rights reserved.

Media Contact

Richard Brewer-Hay

Splunk Inc.

[email protected]

Investor Contact

Ken Tinsley

Splunk Inc.

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Posted on

Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration

  • Data showed reduction of neovascular lesion formation and vascular leakage in a rodent model of choroidal neovascularization

  • ABP201 performed equally or better than aflibercept in lesion inhibition and vascular leakage

WOBURN, Mass., May 04, 2021 (GLOBE NEWSWIRE) — Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today announced results from its study of ABP201, a novel bispecific antibody co-targeting VEGF and ANG2, for treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Results were also shared in a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on Monday May 3rd, 2021.

“The results from our preclinical study are very encouraging for the potential of ABP201 to treat patients affected by Wet AMD and DME,” said Ian Chan, chief executive officer of Abpro. “Bispecific antibody-based treatments for vascular diseases of the eye are promising. This data, which demonstrate equal or better performance to the standard of care in these animal models of neovascularization, is a significant step forward in the company’s ophthalmology program and warrants further evaluation of ABP201 in clinical, in-human studies.”

The study assessed the activity of ABP201 for the treatment of angiogenetic eye pathologies, using a rat laser-induced choroidal neovascularization (CNV) disease model. Abpro is developing ABP201 to treat vascular diseases of the eye, namely diabetic macular edema and wet age-related macular degeneration, that are a result of abnormal neovascularization. ABP201 is a novel tetravalent, bispecific antibody co-targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2), both of which play a role in angiogenic pathways.

Study Conclusions:

  • ABP201 reduced neovascular lesion formation and vascular leakage in the rodent model of CNV.
  • ABP201 performed equally or better than aflibercept/Eylea for inhibition of lesion formation and vascular leakage.
  • This treatment could improve the efficacy and durability compared to the current VEGF therapies on the market.

About Abpro 
  
Abpro Corporation is a clinical stage biotechnology company located in Woburn, Massachusetts. The Company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro’s DiversImmuneTM platform has been used successfully to generate monoclonal antibody therapies against 300 traditionally difficult targets. The DiversimmuneTM platform combines nano-immunology, next-generation sequencing, advanced engineering and bioinformatics to create monoclonal antibody therapies against traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas. For more information, please visit www.abpro.com.  

Media Contact 
Michael Tattory 
LifeSci Communications 
1 (646) 751-4362 
[email protected]



Posted on

MineralTree to Showcase AP Automation Capabilities for Medical Practice Organizations at MGMA 2021 Conference

MGMA Medical Practice Excellence: Pathways Conference Digital Experience

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) — MineralTree, an Accounts Payable (AP) and payments automation solution provider will be a featured sponsor at the Medical Group Management Association’s (MGMA) 2021 Medical Practice Excellence: Pathways Conference Digital Experience (MPE: Pathways Conference DX), taking place virtually from May 11-13, 2021.

MineralTree, a Corporate Member of MGMA, will be showcasing its accounts payable and payment automation platform and how it helps medical practice organizations streamline invoice capture and approvals, minimize paper-based payment processes, simplify financial audits, and take advantage of virtual cards and the valuable discounts and rebates that come with them.

The theme of this year’s MGMA conference is Follow Your Path: Finance | Operations | Data. The conference brings healthcare professionals together to choose the path that fits their day-to-day roles and responsibilities, and offers attendees access to the latest healthcare operations, data and financial education. The MPE: Pathways Conference DX will showcase five content tracks, 30 sessions, 50 speakers and opportunities to network with 2,000+ peers in a state-of-the-art digital experience.

Healthcare professionals can register here. Information on speakers, session details and schedule for the DX. Join the conversation on social media by following MGMA on Facebook, Twitter and LinkedIn.

About MGMA

Founded in 1926, the Medical Group Management Association (MGMA) is the nation’s largest association focused on the business of medical practice management. MGMA consists of 15,000 group medical practices ranging from small private medical practices to large national health systems representing more than 350,000 physicians. MGMA helps nearly 60,000 medical practice leaders and the healthcare community solve the business challenges of running practices so that they can focus on providing outstanding patient care. Specifically, MGMA helps its members innovate and improve profitability and financial sustainability, and it provides the gold standard on industry benchmarks such as physician compensation. The association also advocates extensively on its members’ behalf on national regulatory and policy issues. To learn more, go to MGMA.com or follow us on LinkedIn, Twitter and Facebook.

About MineralTree

MineralTree provides modern, secure, easy-to-use, end-to-end Accounts Payable (AP) Automation solutions that reduce costs by more than 75%, increase visibility and control, and mitigate fraud and risk, while improving cash flow. More than 3,000 mid-market and mid-enterprise companies, as well as more than 30 financial institutions rely on MineralTree to digitize and optimize the entire AP Automation and Payments process, preserving control over the complete invoice-to-payment workflow, improving vendor relationships, maximizing ROI, and transforming the finance function from a cost center to a profit center. For more information, visit https://www.mineraltree.com.



Media Inquiries
Tim Walsh
617.512.1641
[email protected]

Posted on

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR

Data Presented in a Poster at the Pediatric Academic Societies Annual Meeting

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the presentation of positive behavioral outcomes data from the Company’s ongoing open-label extension study (C602) of DCCR (diazoxide choline) Extended-Release tablets for patients with Prader-Willi Syndrome (PWS), at the Pediatric Academic Societies (PAS) 2021 Virtual Annual Meeting. The poster is available here.

As part of the ongoing Phase 3 program of DCCR in PWS, interviews are being conducted with caregivers of C602 study participants to characterize individual patient experiences with DCCR. The interviews are performed at multiple timepoints during the Phase 3 program by Casimir Inc., a rare disease research organization. The poster highlights the analysis of a subset of 48 interviews of caregivers whose child had received at least 13 weeks of DCCR treatment in C602. Folia Health, which utilizes a data driven platform to improve the treatment of chronic conditions, utilized a combination of natural language processing (NLP) and qualitative analytic techniques to process and analyze the transcript data from the caregiver interviews.

Through the 48 interviews, 39 behavioral outcomes were identified in seven outcome domains, with an average of 22±5.9 behaviors reported. The three most frequently reported domains were Food-seeking Behaviors (100%), Mealtime Behaviors (98%), and Daily Life Behaviors (98%). Twenty three percent of participants reported a negative behavior change and 6% reported more than one negative change. Most participants (83%) reported positive change in one or more behavioral outcomes on DCCR, more than 70% reported positive changes in one quarter or more of behaviors, while 48% reported positive changes in more than half of behaviors.

“It is exciting to see the utilization of natural language processing for the first time to determine caregiver sentiment in patients with PWS. NLP and other artificial intelligence techniques are the future of qualitative data analysis and can be particularly useful in rare-disease research. To my knowledge, this is the first report of the use of such techniques to understand the complex world of PWS outcomes,” said Deepan Singh, M.D., Vice Chair of Ambulatory Psychiatry, Maimonides Medical Center in Brooklyn, NY. “Behavioral abnormalities in PWS are heterogenous and very difficult to treat. I am encouraged by DCCR’s potential to impact these intractable problematic behaviors in individuals with PWS.”

“These important data provide critical insights into the long-term behavioral responses to DCCR in PWS, and support a more complete view of this promising investigational drug’s therapeutic benefits,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “The growing body of clinical evidence continues to indicate that DCCR has the potential to address the significant need for a safe and effective treatment for individuals with PWS. We remain firmly committed to working with the U.S. Food and Drug Administration to define the path forward for DCCR.”

About PWS

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births in the U.S. The hallmark symptom of this disorder is hyperphagia, a chronic feeling of insatiable hunger that severely diminishes the quality of life for PWS patients and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant morbidities (e.g., obesity, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parent and caregivers) rated hyperphagia as the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder. Diazoxide choline has received Orphan Drug Designation for the treatment of PWS in the U.S. and EU, and Fast Track Designation in the U.S.

About DCCR (Diazoxide Choline) Extended-Release Tablets

DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of patients in a few rare diseases in neonates, infants, children and adults, but has not been approved for use in PWS. Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide and DCCR in patients with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in PWS patients. In the PWS Phase 3 study, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

About Casimir Inc.

Casimir is a Contract Research Organization (CRO) that develops novel outcomes for decentralized and hybrid trials in order to better understand disease progression and treatment benefit. Casimir works with sponsors in over 20 rare diseases in every facet of clinical services from preclinical development to Phase IV and siteless studies. 

About Folia Health

Folia is a patient-driven Health-IOS (Individual Operating System) that enables individuals to easily take an active role in their care, while contributing to precision diagnostics, patient-centered drug development, & better care for complex diseases. Folia’s rich longitudinal data and proprietary analytic methods provide a vital and missing piece in the emergence of a home-centered, data-driven healthcare ecosystem. Discover how to harness the power of patient and caregiver knowledge at www.foliahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company’s prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Posted on

TheMaven, Inc. Adopts Limited-Duration Stockholder Rights Plan

TheMaven, Inc. Adopts Limited-Duration Stockholder Rights Plan

NEW YORK–(BUSINESS WIRE)–
TheMaven, Inc. (OTC: MVEN) (“Maven” or the “Company”), a best-in-class technology platform empowering premium publishers who impact, inform, educate and entertain, today announced that the Special Finance & Governance Committee (the “Special Committee”) of the Maven Board of Directors (the “Board”) has adopted a limited-duration stockholder rights plan (the “Rights Plan”) to protect the best interests of all of the Company’s stockholders. The Rights Plan is effective immediately and will expire on May 3, 2022.

The adoption of the Rights Plan is intended to assure that all stockholders of the Company receive fair and equal treatment in the event of a proposed takeover of the Company, to guard against two-tier or partial tender offers, open market accumulations and other tactics designed to gain control of the Company without paying all stockholders a fair and adequate price, including sufficient premium for such controlling interest, and to enhance the Board’s ability to negotiate with a prospective acquiror. The Rights Plan is similar to those adopted by other publicly traded companies and includes a number of recognized stockholder protections that emphasize its limited focus and duration.

“The Maven Board of Directors is committed to creating long-term value and ensuring that our stockholders are able to realize the full potential of their investment in the Company,” said Maven Chairman John A. Fichthorn. “In the last year, we have made significant progress related to our financial reporting, a process that is nearing its conclusion. Accordingly, we believe that the Rights Plan adopted today will provide the Board with the flexibility to protect the best interests of the Company and its stockholders, and would still enable Maven to consider any legitimate offer that is fair and otherwise in the best interest of all stockholders. We remain focused on generating value for stockholders by growing the business and building on our position as a best-in-class technology and media company.”

In adopting the Rights Plan, the Special Committee declared a dividend distribution of one preferred stock purchase right (a “Right”) on each outstanding share of its common stock and the common stock issuable upon conversion of each share of the Company’s preferred stock. Each Right will initially entitle stockholders to buy one one-thousandth of a share of newly created Series L Junior Participating Preferred Stock of the Company, at an exercise price of $4.00, in the event the Rights become exercisable, subject to adjustment and the terms of the Rights Plan agreement.

In general, the Rights will become exercisable only if a person or group becomes the beneficial owner of 15% or more of the outstanding common stock of the Company or announces a tender offer for 15% or more of the outstanding common stock of the Company, including through such person’s ownership of the Company’s convertible preferred stock, as further detailed in the Rights Plan. The Board of Directors will, in general, be entitled to redeem the Rights at $0.001 per Right at any time before the triggering ownership threshold is crossed. Any stockholders with beneficial ownership of 15% or more of the outstanding common stock of the Company as of the time of this announcement are generally grandfathered at their current ownership levels, but the Rights Plan does not permit such shareholders to increase their ownership without triggering the Rights Plan.

This announcement is a summary only and is qualified by reference to the full text of the Rights Plan. Additional details regarding the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities & Exchange Commission on or about May 4, 2021.

About Maven

Maven (maven.io) is a technology platform empowering premium publishers who impact, inform, educate and entertain. Maven operates Sports Illustrated Media and TheStreet, and powers more than 150 online destinations. Maven is publicly traded under the ticker symbol “MVEN”.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and include, without limitation, statements concerning the Company’s business strategy, future revenues, market growth, capital requirements, product introductions, and expansion plans and the adequacy of its funding. Other statements contained in this press release that are not historical facts are forward-looking statements. The Company has tried, wherever possible, to identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and other comparable terminology.

The Company cautions you that any forward-looking statements presented in this press release are based on the beliefs of, assumptions made by, and information currently available to, us. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond the Company’s control or ability to predict. Although the Company believes that its assumptions are reasonable, they are not guarantees of future performance, and some will inevitably prove to be incorrect. As a result, the Company’s actual future results can be expected to differ from its expectations, and those differences may be material. Accordingly, you should use caution in relying on forward-looking statements, which are based only on known results and trends at the time they are made, to anticipate future results or trends. Certain risks are discussed from time to time in the Company’s filings with the SEC, including but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequently filed quarterly reports on Form 10-Q.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company is not obligated to publicly release any revisions to these forward-looking statements to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Rachael Fink

Communications Manager, Maven

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Entertainment Communications Other Entertainment Technology Other Technology Software Other Communications

MEDIA: